Success Metrics

Completion Rate

0%(0/1)

Active Trials

4(80%)

Terminated

1(20%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Terminated(1)

Detailed Status

Active, not recruiting3

Terminated1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

terminated120%

active_not_recruiting360%

recruiting120%

Recent Activity

4 active trials

Showing 5 of 5

active_not_recruitingphase_1

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

NCT03219450

terminatedphase_1

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT03422094

Clinical Trials (5)

Showing 5 of 5 trials

NCT04930783Phase 1

NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma

Active Not Recruiting

NCT02950766Phase 1

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

Active Not Recruiting

NCT04024878Phase 1

NeoVax With Nivolumab in Patients With Ovarian Cancer

Active Not Recruiting

NCT03219450Phase 1

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Recruiting

NCT03422094Phase 1

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Terminated

All 5 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 5